Page 159 - rcv31n3.vp

Revista Uruguaya de Cardiología Prevención cardiovascular en el diabético
Volumen 31 | nº 3 | Diciembre 2016 Washington Vignolo, Bernardo Layerle

9];28(5):1151-7. Disponible en: http://www.ncbi. 2016 Jul;68(1):92-125.
nlm.nih.gov/pubmed/15855581. doi:10.1016/j.jacc.2016.03.519.
92. Heart Protection Study Collaborative Group. 100. LaRosa JC, Grundy SM, Waters DD, Shear C,
MRC/BHF Heart Protection Study of cholesterol lo- Barter P, Fruchart JC, et al. Intensive lipid lowe-
wering with simvastatin in 20,536 high-risk indivi- ring with atorvastatin in patients with stable coro-
duals: a randomised placebo controlled trial. Lancet. nary disease. N Engl J Med. 2005 Apr 7;352(14):
2002 July 6;360(9326):7-22. 1425-35. doi:10.1056/NEJMoa050461.
doi:10.1016/S0140-6736(02)09327-3.
101. Cannon CP, Braunwald E, McCabe CH, Rader
93. Collins R, Armitage J, Parish S, Sleigh P, Peto DJ, Rouleau JL, Belder R, et al; for the Pravas-
R; Heart Protection Study Collaborative tatin or Atorvastatin Evaluation and Infection
Group. MRC/BHF Heart Protection Study of choles- Therapy-Thrombolysis in Myocardial Infarc-
terol-lowering with simvastatin in 5963 people with tion 22 Investigators. Comparison of Intensive
diabetes: a randomised placebo-controlled trial. Lan- and Moderate Lipid Lowering with Statins after Acu-
cet. 2003 Jun14 [citado 2016 Oct te Coronary Syndromes. 2004 Apr 8;350:1-10.
9];361(9374):2005-16. Disponible en: http://www.
102. Ridker PM, Danielson E, Fonseca FAH, Genest
ncbi.nlm.nih.gov/pubmed/12814710.
J, Gotto AM Jr, Kastelein JJ, et al; JUPITER
94. Cholesterol Treatment Trialists’ (CTT) Colla- Study Group. Rosuvastatin to Prevent Vascular
boration. Efficacy and safety of more intensive lo- Events in Men and Women with Elevated C-Reactive
wering of LDL cholesterol: a meta-analysis of data Protein. N Engl J Med. 2008 Nov 20;
from 170 000 participants in 26 randomised trials. 359(21):2195-207.
Lancet. 2010 Nov 13;376(9753):1670-81.
103. Cannon CP, Blazing MA, Giugliano RP,
doi:10.1016/S0140-6736(10)61350-5.
McCagg A, White JA, Theroux P, et al;
95. Cholesterol Treatment Trialists’ (CTT) Colla- IMPROVE-IT Investigators. Ezetimibe Added to
borators, Kearney PM, Blackwell L, Collins R, Statin Therapy after Acute Coronary Syndromes. N
Keech A, Simes J, Peto R, et al. Efficacy of choles- Engl J Med. 2015 Jun 18;372(25):2387-97.
terol-lowering therapy in 18,686 people with diabetes doi:10.1056/NEJMoa1410489.
in 14 randomised trials of statins: a meta-analysis. 104. Chapman MJ, Redfern JS, McGovern ME, Gi-
Lancet. 2008 Jan 12;371(9607):117-25. ral P. Niacin and fibrates in atherogenic dyslipide-
doi:10.1016/S0140-6736(08)60104-X. mia: pharmacotherapy to reduce cardiovascular risk.
96. Cannon CP, Braunwald E, McCabe CH, Rader Pharmacol Ther. 2010 Jun;126(3):314-45.
DJ, Rouleau JL, Belder R, et al. Intensive versus doi:10.1016/j.pharmthera.2010.01.008.
moderate lipid lowering with statins after acute coro- 105. The FIELD study investigators. Effects of
nary syndromes. N Engl J Med. 2004 Apr long-term fenofibrate therapy on cardiovascular
8;350(15):1495-504. doi:10.1056/NEJMoa040583. events in 9795 people with type 2 diabetes mellitus
(the FIELD study): randomised controlled trial. Lan-
97. Ahmed S, Cannon CP, Murphy SA, Braunwald
cet. 2005 Nov 26;366(9500):1849-61.
E. Acute coronary syndromes and diabetes: is inten-
doi:10.1016/S0140-6736(05)67667-2.
sive lipid lowering beneficial? Results of the PROVE
IT-TIMI 22 trial. Eur Heart J. 2006 106. Rubins HB, Robins SJ, Collins D, Nelson DB,
Oct;27(19):2323-9. doi:10.1093/eurheartj/ehl220. Elam MB, Schaefer EJ, et al. Diabetes, plasma in-
sulin, and cardiovascular disease: subgroup analysis
98. Stone NJ, Robinson JG, Lichtenstein AH, Bai-
from the Department of Veterans Affairs high-den-
rey Merz CN, Blum CB, Eckel RH, et al. 2013
sity lipoprotein intervention trial (VA-HIT). Arch
ACC/AHA guideline on the treatment of blood cho-
Intern Med. 2002 Dec 9-23 [citado 2016 May
lesterol to reduce atherosclerotic cardiovascular risk
16];162(22):2597-604. Disponible en: http://www.
in adults: a report of the American College of Cardio-
ncbi.nlm.nih.gov/pubmed/12456232.
logy/American Heart Association Task Force on
Practice Guidelines. J Am Coll Cardiol. 2014 Jul 107. Saha SA, Arora RR. Fibrates in the prevention of
1;63(25 Pt A):2889-934. cardiovascular disease in patients with type 2 diabe-
doi:10.1016/j.jacc.2013.11.002. tes mellitus - A pooled meta-analysis of randomized
placebo-controlled clinical trials. Int J Cardiol. 2010
99. Lloyd-Jones DM, Morris PB, Ballantyne CM,
May 28;141(2):157-66.
Birtcher KK, Daly DD Jr, DePalma SM, et al.
doi:10.1016/j.ijcard.2008.11.211.
2016 ACC Expert Consensus Decision Pathway on
the Role of Non-Statin Therapies for LDL-Choleste- 108. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls
rol Lowering in the Management of Atherosclerotic SJ, et al. Effects of fibrates on cardiovascular outco-
Cardiovascular Disease Risk: A Report of the Ameri- mes: a systematic review and meta-analysis. Lancet.
can College of Cardiology Task Force on Clinical 2010 May 29;375(9729):1875-84.
Expert Consensus Documents. J Am Coll Cardiol. doi:1 0.1016/S0140-6736(10)60656-3.
503